Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects

Phase 1 Completed 148 enrolled Bristol-Myers Squibb

RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single and multiple oral doses of BMS-986141 in healthy subjects.

Timeline

Start: 2014-09
Primary completion: 2015-09
Completion: 2015-09

Publications

Merali S, Wang Z, Frost C, Meadows-Shropshire S, Hawthorne D, Yang J, Seiffert D. First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants. Platelets. 2023 Dec;34(1):2222846. doi: 10.1080/09537104.2023.2222846.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BMS-986141	Small molecule	2.5 mg	Oral
Subject	BMS-986141	Small molecule	75 mg	Oral
Subject	BMS-986141	Small molecule	150 mg	Oral
Background	Aspirin	Small molecule	—	Oral
Background	Itraconazole	Small molecule	—	Oral

Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects

Summary

Timeline

Publications

Drugs

Indications